PODD · NASDAQ · CIK 0001145197
Insulet Corporation
No equity stake in another company appears in Insulet Corporation's filings. That is the sourced answer, not a hole in the research.
Insulet Corporation - Profile
- Sector
- Health CareGICS
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
- Listed on
- Nasdaq
- Employees
- 5,400stated 2025
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Insulet Corporation's own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The website was checked for this site against the company's own pages. The headcount is the figure the sources below state for 2025. The description was written for this site in August 2026 from Insulet Corporation Form 10-K for the year ended December 31, 2025, Insulet Reports Fourth Quarter and Full Year 2025 Results and About Insulet, not taken from any single article.
Share price
PODD
Description
Insulet Corporation designs, manufactures and sells the Omnipod family of tubeless, wearable insulin pumps for people with insulin dependent diabetes, comprising the Omnipod 5 automated insulin delivery system, the Omnipod DASH insulin management system and the original Omnipod. Revenue is recurring, because customers keep buying the disposable pods that hold and deliver the insulin. Total revenue rose 30.7% to $2.71 billion in 2025, split between $1.92 billion of Omnipod sales in the United States, $754.3 million internationally and $34.1 million of drug delivery revenue, almost all of it pods supplied to Amgen for the Neulasta Onpro kit. The company is based in Acton, Massachusetts, is listed on Nasdaq and employed about 5,400 full time staff at 31 December 2025.
Who owns Insulet Corporation.
sized by
modelled, reported or pending
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 773 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
773 managers reported a position, together holding 69.6m shares, or 100.4% of the company. The 40 largest are listed. Percentages are of the 69.3m shares outstanding at 29 Apr 2026, the count in force when this quarter was measured rather than the count today.
This adds up to more than the whole company, and that is what the filings say. A 13F total can exceed 100% because the same share can be reported twice: when a holder lends stock, the borrower sells it to someone else, and both the lender's manager and the new buyer's manager report it. The gap tracks how heavily a stock is shorted. It is a property of 13F rather than a fault in this data, so it is shown as filed, and it cannot be used as evidence that a particular holder's stake is large.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Holdings side: searched Insulet's most recent 10-Q (period 30 Jun 2026, filed 5 Aug 2026) and most recent 10-K (fiscal year ended 31 Dec 2025, filed 18 Feb 2026, including Exhibit 21.1 subsidiaries list) for 'equity method', 'equity investment', 'non-marketable', 'joint venture', 'investment in', 'Investment in ', 'unrealized gain'. Both filings disclose only a COMBINED balance: 'the total carrying value of the Company's investments in equity securities without readily determinable fair values was $19.1 million at both June 30, 2026 and December 31, 2025' (and $21.9 million at 31 Dec 2024), carried within 'other assets' on the balance sheet, measured at cost less impairment. The 10-K adds that 'During the year ended December 31, 2025, the Company made a strategic investment in equity securities of a privately held entity in the amount of $12.0 million' and recorded a $2.8 million impairment on 'one equity security' in 2025, but at no point names the investee(s). Per this project's rule that a combined equity-method or cost-method balance covering unnamed or multiple investees sizes none of them individually, no holdings row is created; the $19.1 million bucket is recorded here as a genuine but unsized negative rather than a gap left to speak for itself.
- Exhibit 21.1 of the 10-K (subsidiaries list) was checked as the brief suggests: it is a bare name/jurisdiction list of Insulet's own wholly owned operating subsidiaries (Insulet Canada Corporation, Insulet France SAS, Sub-Q Solutions Inc and others), no ownership-percentage column, and no private-company investee named anywhere on it. Treated as a genuine negative, consistent with the $19.1 million equity-securities bucket being the only holdings-adjacent disclosure in either filing.
- Insulet's 0.375% Convertible Senior Notes due September 2026 are Insulet's OWN debt, issued by the company, not a holding: the 10-K describes the 2025 repurchase and redemption of this instrument (Note 13, Debt) and by 31 Dec 2025 the balance was fully retired ($0 outstanding at both 31 Dec 2025 and reflected in the Q2 2026 10-Q debt table). Confirmed not to be confused with any equity holding per the brief's specific warning about Insulet's convertible notes.
- Self-gate computed from this final file: 12 register rows, no row rolls up into another (the directors/executive-officers aggregate has no individually broken-out members, so it counts at full value per the brief's own rule for an aggregate with no members), total shares = 8,336,382 (Vanguard family) + 6,690,192 (BlackRock) + 3,197,555 (State Street) + 2,455,135 (AQR) + 2,042,313 (Baillie Gifford) + 2,003,861 (Geode) + 1,726,509 (T. Rowe Price family) + 1,319,381 (Clearbridge) + 964,297 (FMR) + 328,025 (Capital Group family) + 119,351 (American Century) + 250,199 (directors/officers aggregate) = 29,433,200 shares, against shares_outstanding 69,354,199 = 42.44% of the company. This sits within the brief's expected 25-45% band.
- Implied per-share price check across every institutional row (all dated 30 Jun 2026, all CUSIP 45784P101 common stock): Vanguard family ~$152.24, BlackRock ~$152.25, State Street ~$152.25, AQR ~$152.25, Baillie Gifford ~$152.28, Geode ~$151.68, T. Rowe Price family ~$152.25 (after converting BOTH T. Rowe registrants' reported dollar values from thousands), Clearbridge ~$152.25, FMR ~$152.24, Capital Group family ~$152.25, American Century ~$152.25. All eleven cluster tightly around $152.25/share, confirming one consistent instrument and basis and validating the T. Rowe Price thousands conversion independently.
- Two register rows disagree sharply with the stale 5%-owner table in the 2026 DEF 14A, which sources its figures from old Schedule 13G/A filings rather than a fresh 13F: BlackRock's proxy figure (6,102,546 sh, 8.7%, as of 31 Dec 2023) is lower than the fresh Q2 2026 13F (6,690,192 sh); Capital Research Global Investors' proxy figure (7,772,404 sh, 11.1%, as of 30 Sep 2024) and FMR's proxy figure (6,306,854 sh, 9.0%, as of 31 Dec 2025) are both dramatically higher than their respective fresh Q2 2026 13F figures (155,313 sh for Capital Research Global Investors alone; 964,297 sh for FMR). Both reflect substantial institutional selling during a period in which PODD's share price fell sharply (52-week range $126.40 to $354.88 per the Nasdaq quote fetched 19 Aug 2026). The fresh 13F figures are used in the register rows per this project's standing rule to prefer the current 13F over a stale proxy-quoted 13G.
- Capital International Investors (CIK 0001562230), the third of the three Capital Group registrants checked, holds NOTHING in Insulet as of the Q2 2026 13F-HR (filed 12 Aug 2026): its information table has no row for CUSIP 45784P101. Recorded here as a note, not a null row, per this project's rule that a checked-and-zero holder is not a register row.
- Market cap is a computed figure: a live intraday Nasdaq quote ($152.14, 19 Aug 2026 3:20pm ET) multiplied by the 29 Jul 2026 10-Q cover-page share count (69,354,199). The two dates are about three weeks apart because no single filing carries both a current price and a current share count; disclosed rather than treated as precise.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Only three Capital Group registrants (Capital Research Global Investors, Capital World Investors, Capital International Investors) were checked; the brief documents cases where up to six Capital Group registrants hold a given issuer, so a further Capital Group entity holding Insulet cannot be ruled out without checking the full family.
- No SC 13D or SC 13G/A has been filed against Insulet stock since the 12 Nov 2024 Capital Research Global Investors amendment and the 25 Jan 2024 BlackRock amendment (checked against the full EDGAR filing history through 19 Aug 2026), so any strategic or sovereign holder crossing 5% since those dates but staying outside the institutional 13F names checked here would not be caught by this search.
- Named individual director and executive officer holdings from the 2026 DEF 14A (including CEO Timothy C. Stonesifer at 4,223 shares) were read but not itemized as separate register rows, since none reaches 1% of the company individually; only the 18-person aggregate is recorded.
- Market cap is a computed figure (live price times a 29 Jul 2026 share count, roughly three weeks apart), not read directly from a single page stating market cap; see the corresponding note.